Oncotalks hematology videos and news

EHA 2019 Prof. James Bussel, MD - PATIENT PERCEPTIONS ON SPLENECTOMY OUTCOMES: RESULTS FROM THE ITP WORLD IMPACT SURVEY (I-WISH)

Prof. James Bussel, MD from the Well Cornel Medicine, New York, USA is commenting on the publication PATIENT PERCEPTIONS ON SPLENECTOMY OUTCOMES: RESULTS FROM THE ITP WORLD IMPACT SURVEY (I-WISH) presented at the EHA 2019 congress in Amsterdam


Reference: EHA Library. Cooper N. Jun 14, 2019; 266513

Link to abstract: https://library.ehaweb.org/eha/2019/24th/266513/nichola.cooper.patient.perceptions.on.splenectomy.outcomes.results.from.the.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dpatient+perceptions%2Bsplenectomy+outcomes%3A+results%2Bitp+world+impact+survey+%28i-wish

Related items

EHA Prof. James Bussel, MD - TAPERING AND DISCONTINUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN ITP: EXPERT CONSENSUS OPINIONS

EHA Prof. James Bussel, MD - TAPERING AND DISCONTINUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN ITP: EXPERT CONSENSUS OPINIONS

Prof. James Bussel from the Well Cornel Medicine, New York, USA is commenting on the abstract MD TAPERING AND DISCONTINUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN ITP: EXPERT CONSENSUS OPINIONS which was presented at EHA 2019 in AmsterdamReference: EHA Library. Cooper N. Jun 14, 2019; 266508Link: https://library.ehaweb.org/eha/2019/24th/266508/nichola.cooper.tapering.and.discontinuation.of.thrombopoietin.receptor.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3D+TAPERING+AND+DISCONTINUATION+OF+THROMBOPOIETIN+RECEPTOR+AGONISTS+IN+ITP%3A+EXPERT+CONSENSUS+OPINIONS
EHA , Lithuania , Albania
00:07:29
EHA 2019 Prof. James Bussel, MD - LONG-TERM OVERUSE OF CORTICOSTEROIDS IN THE REAL-WORLD TREATMENT OF PATIENTS WITH ITP

EHA 2019 Prof. James Bussel, MD - LONG-TERM OVERUSE OF CORTICOSTEROIDS IN THE REAL-WORLD TREATMENT OF PATIENTS WITH ITP

Prof. James Bussel, MD from the Well Cornel Medicine, New York, USA is commenting on the abstract LONG-TERM OVERUSE OF CORTICOSTEROIDS IN THE REAL-WORLD TREATMENT OF PATIENTS WITH IMMUNE THROMBOCYTOPENIA IN THE US EXPLORYS AND MARKETSCAN DATABASES which he presented at EHA 2019 in AmsterdamReference: EHA Library. Bussel J. Jun 14, 2019; 266509Link to abstract: https://library.ehaweb.org/eha/2019/24th/266509/j.bussel.long-term.overuse.of.corticosteroids.in.the.real-world.treatment.of.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3DLONG-TERM+OVERUSE+OF+CORTICOSTEROIDS+IN+THE+REAL-WORLD+TREATMENT+OF+PATIENTS+WITH+IMMUNE+THROMBOCYTOPENIA+IN+THE+US+EXPLORYS+AND+MARKETSCAN+DATABASES
Lithuania , Albania
00:06:00
EHA 2019 Prof. James Bussel, MD - PHYSICIANS' PERCEPTIONS ON CAUSES OF PRIMARY AND SECONDARY ITP AND LEADING CAUSES OF MISDIAGNOSIS: RESULTS FROM THE ITP WORLD IMPACT SURVEY (I-WISH)

EHA 2019 Prof. James Bussel, MD - PHYSICIANS' PERCEPTIONS ON CAUSES OF PRIMARY AND SECONDARY ITP AND LEADING CAUSES OF MISDIAGNOSIS: RESULTS FROM THE ITP WORLD IMPACT SURVEY (I-WISH)

Prof. James Bussel, MD from the Well Cornel Medicine, New York, USA is commenting on the abstract PHYSICIANS' PERCEPTIONS ON CAUSES OF PRIMARY AND SECONDARY ITP AND LEADING CAUSES OF MISDIAGNOSIS: RESULTS FROM THE ITP WORLD IMPACT SURVEY (I-WISH) which was presented at EHA 2019 in Amsterdam.Reference: EHA Library. Bussel J. Jun 14, 2019; 266511Link to abstract https://library.ehaweb.org/eha/2019/24th/266511/j.bussel.physicians.perceptions.on.causes.of.primary.and.secondary.itp.and.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dmisdiagnosis%3A+results%2Bitp+world+impact+survey+%28i-wish%29
Lithuania , Albania
00:06:09
ESMO 2019 Valentina Guarneri, MD, PhD; Overall survival (OS) results of the Phase III MONALEESA-3 trial

ESMO 2019 Valentina Guarneri, MD, PhD; Overall survival (OS) results of the Phase III MONALEESA-3 trial

Valentina Guarneri, MD, PhD from the University of Padua, Padua, Italy is commenting on the abstract: LBA7_PR - Overall survival (OS) results of the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)
ESMO , Kisqali Channel , Latvia , Lithuania , Estonia , Hungary , Albania
00:03:29